Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Research & Development (2018 - 2025)

TransMedics has reported Research & Development over the past 8 years, most recently at $20.7 million for Q4 2025.

  • Quarterly results put Research & Development at $20.7 million for Q4 2025, up 25.73% from a year ago — trailing twelve months through Dec 2025 was $69.1 million (up 23.38% YoY), and the annual figure for FY2025 was $69.1 million, up 23.38%.
  • Research & Development for Q4 2025 was $20.7 million at TransMedics, up from $15.3 million in the prior quarter.
  • Over the last five years, Research & Development for TMDX hit a ceiling of $20.7 million in Q4 2025 and a floor of $4.5 million in Q1 2021.
  • Median Research & Development over the past 5 years was $9.5 million (2023), compared with a mean of $10.5 million.
  • Biggest five-year swings in Research & Development: fell 27.2% in 2021 and later soared 93.83% in 2024.
  • TransMedics' Research & Development stood at $6.3 million in 2021, then decreased by 8.84% to $5.8 million in 2022, then skyrocketed by 86.95% to $10.8 million in 2023, then surged by 53.0% to $16.5 million in 2024, then grew by 25.73% to $20.7 million in 2025.
  • The last three reported values for Research & Development were $20.7 million (Q4 2025), $15.3 million (Q3 2025), and $15.9 million (Q2 2025) per Business Quant data.